Prenosis Secures $20M in Series A Funding to Advance Integrated Diagnostics and Therapeutics

Prenosis did not wake up one morning and decide to chase sepsis. Sepsis chased them first. Chicago-based, founded in June 2014, Prenosis came out of a collision between the University of Illinois lab bench and the ICU floor. Bobby Reddy Jr., PhD watched his father move through a system built on averages and protocols instead of biology. Rashid Bashir, PhD was building microfluidic and bioanalytical technology inside the University of Illinois at Urbana Champaign. One saw the human cost. The other saw the molecular truth. Prenosis became the place where those two realities were finally forced to shake hands.

Prenosis just pulled in $40 million in fresh fuel without blinking. $20 million in Series A capital led by PACE Healthcare Capital. $20 million more through a BARDA contract under the Type to Treat program. Private capital meets federal conviction. Equity meets urgency. The kind of alignment you only see when the problem is big enough that nobody argues about whether it matters.

The product pulling this gravity is Sepsis ImmunoScore®, the first FDA De Novo–authorized AI diagnostic for sepsis. Not a black box. Not a vibes-based alert. This system ingests up to twenty-two biological and clinical parameters, lives inside the EMR, and tells clinicians two things that actually matter. Is this patient septic, and are they about to fall off a cliff in the next twenty-four hours. TIME called it one of the Best Inventions of 2024. The New England Journal of Medicine AI published the data. Hospitals got an ICD-10 code so finance stopped asking questions.

Prenosis does not sell software. They sell clarity at the moment when clarity is usually missing. Their Immunix™ platform is built on one of the largest purpose-built acute care biobanks in the country, more than 120,000 blood samples tied to real clinical outcomes. That biology-first posture is why Roche Diagnostics distributes the ImmunoScore, why Labcorp is in the room, why Foxconn is manufacturing point-of-care devices, and why up to forty academic medical centers are about to become a precision-medicine trial network instead of isolated silos.

This funding pushes Prenosis past diagnosis and straight into consequence. The BARDA program backs an 800-patient randomized controlled trial using an AI-driven steroids companion diagnostic for severe respiratory infection. Translation matters here. Some patients need steroids. Some get hurt by them. Prenosis is building the map that tells the difference in real time, not in hindsight.

Bobby Reddy Jr., PhD and Rashid Bashir, PhD are not chasing scale for applause. They are stacking evidence until acute care stops guessing. Sepsis still hits 1.7 million Americans a year and accounts for one in three hospital deaths. Prenosis is betting that biology, when respected, changes that math, and the rest of the system is about to find out whether it is ready to keep up.